Innate Pharma
IPHA
8 hedge funds and large institutions have $361K invested in Innate Pharma in 2023 Q4 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 8 → 8 (0)
0.24% less ownership
Funds ownership: 0.4% → 0.16% (-0.24%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
55% less capital invested
Capital invested by funds: $806K → $361K (-$445K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
+$29.5K |
| 2 |
Morgan Stanley
New York
|
+$3.47K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Optiver Holding
Amsterdam,
Netherlands
|
-$416K |
| 2 |
Millennium Management
New York
|
-$86.8K |
| 3 |
SPIA
Steward Partners Investment Advisory
New York
|
-$744 |
IPHA Hedge Fund Activity: Q4 2023 in Review
8 of the 6,871 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q4 2023, worth a combined $361K — down 55% from $806K a quarter earlier.
Fund positioning in IPHA was balanced in Q4 2023: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 3 trimmed.
The largest buyer was Exchange Traded Concepts, adding an estimated $29.5K. The largest seller was Optiver Holding, cutting an estimated $416K.
- 8 institutional investors held Innate Pharma (IPHA) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $361K of Innate Pharma stock for Q4 2023, down 55% quarter-over-quarter.
- 0 funds opened new Innate Pharma positions in Q4 2023 and 0 closed out.
- The largest Innate Pharma buyer in Q4 2023 was Exchange Traded Concepts, an estimated $29.5K added.
- The largest Innate Pharma seller in Q4 2023 was Optiver Holding, an estimated $416K sold.
Based on aggregated 13F filings for Q4 2023.